Jonathan Berlent Joins Merakris as SVP, Head of Strategy and Operations
09 mai 2024 06h30 HE
|
Merakris Therapeutics
Merakris Therapeutics announced today that Jonathan Berlent has joined the company as Senior Vice President, Head of Strategy and Operations.
Favorable Results From Dermacyte® Matrix Research Study Published in March Issue of Journal of Wound Care
12 mars 2024 06h30 HE
|
Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- A recent multicenter study has demonstrated encouraging effectiveness and safety of Merakris Therapeutics’ Dermacyte® Amniotic Wound...
Merakris Therapeutics to Release Final Part 1 Data From Phase 2 Multicenter Investigational Drug Study for Dermacyte® Liquid
20 févr. 2024 06h15 HE
|
Merakris Therapeutics
Merakris to present encouraging Phase 2 clinical drug trial data at annual Treasure Hunt Podiatry and Wound Conference in Los Angeles, CA, February 24-25.
Merakris To Share Data from Fully Enrolled First Part of Two-Part Dermacyte® Liquid Clinical Trial
05 déc. 2023 06h30 HE
|
Merakris Therapeutics
Merakris Therapeutics announces it has fully enrolled the first part of a clinical trial to evaluate its investigational drug product, Dermacyte® Liquid.
Merakris Announces Nationwide At-Your-Door Autologous Serum Tears Program
12 oct. 2023 06h30 HE
|
Merakris Therapeutics
The Opticyte Tears program uses patients’ blood serum to create Autologous Serum Tears from the convenience of their homes.
Wound Healing Technology Company Merakris Adds Two Executives to Leadership Team
15 août 2023 06h30 HE
|
Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Merakris Therapeutics has added two new executives to its leadership team as it prepares to expand its product line and increase its...
Merakris Announces Review in Biomedicines Medical Journal Highlighting Therapeutic Potential of Cell-Free Amniotic Fluid
29 nov. 2022 06h15 HE
|
Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2022 (GLOBE NEWSWIRE) -- A review published recently in the international scientific journal Biomedicines highlights the therapeutic benefits of amniotic fluid...
Merakris Sponsored Study Opens Door to Precision-Based Approaches to Wound Healing
13 sept. 2022 06h00 HE
|
Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., Sept. 13, 2022 (GLOBE NEWSWIRE) -- A recently published manuscript containing research sponsored, in part, by Merakris Therapeutics has opened the door to more...
First Patient Enrolled in Merakris-Sponsored VA Clinical Trial
27 juil. 2022 06h30 HE
|
Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., July 27, 2022 (GLOBE NEWSWIRE) -- The first patient has been enrolled in a Phase II clinical trial – sponsored by Merakris Therapeutics – to measure the safety and...
Merakris CEO To Discuss Dermacyte® Development Program As Part of Advanced Wound Care Summit Panel in July
28 juin 2022 08h00 HE
|
Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., June 28, 2022 (GLOBE NEWSWIRE) -- About five years ago, the U.S. Food and Drug Administration (FDA) announced plans to toughen its guidelines around the development and...